Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target

Guggenheim analyst Yatin Suneja has reiterated a Buy rating on Neumora Therapeutics (NASDAQ: NMRA) and maintained a price target of $14 for the company's stock.